GlassScriptPhysician profile
Benjamin J Stillman
NPI 1164942207
$4,633.25
in general payments reported to CMS, 2019-2025
35 companies · $724 in 2025
The $724 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.09 · 2020: $175 · 2021: $627 · 2022: $976 · 2023: $1,135 · 2024: $979 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,838.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $765.76 | 2021-2025 | Vraylar, Qulipta |
| Otsuka America Pharmaceutical, INC. | $412.03 | 2020-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $403.26 | 2021-2024 | Airsupra, Farxiga, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $269.14 | 2021-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $255.52 | 2022-2024 | Quviviq |
| Novo Nordisk INC | $247.83 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Corium, LLC | $243.28 | 2021-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $227.08 | 2022-2024 | Jornay Pm |
| Amgen INC. | $225.56 | 2021-2025 | Repatha, Evenity, Repatha |
| Lilly USA, LLC | $219.28 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $209.51 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $173.41 | 2020-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $159.40 | 2020-2025 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $121.46 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $96.46 | 2021-2023 | Qelbree |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $84.80 | 2023-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $83.97 | 2019-2024 | |
| Abbott Laboratories | $48.16 | 2023 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $46.47 | 2023 | Gemtesa |
| Lundbeck LLC | $40.95 | 2023-2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $38.71 | 2021 | |
| Collegium Pharmaceutical, INC. | $32.68 | 2025 | Jornay Pm |
| Exact Sciences Corporation | $26.71 | 2024 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $24.86 | 2023 | |
| Dexcom, INC. | $24.56 | 2023 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $19.90 | 2024 | Zoryve |
| Sunovion Pharmaceuticals INC. | $17.90 | 2022 | |
| Ardelyx, INC. | $17.63 | 2024 | Ibsrela |
| Alkermes, INC. | $16.37 | 2025 | Lybalvi |
| Astellas Pharma US INC | $14.40 | 2023 | Veozah |
| Esperion Therapeutics, INC. | $14.29 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.93 | 2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.70 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.25 | 2022 | |
| Allergan, INC. | $12.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Stillman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.